Patterson Companies Inc.
PDCOBusiness Overview
source: coverage-next-full ticker: PDCO step: "01" title: Business Overview — Segments, Model, and Strategic Position created: 2026-05-29
Step 01: Business Overview
Company Description
Patterson Companies, Inc. is one of North America's largest distributors of dental and animal health products. Founded in 1877 as a dental supply company in St. Paul, Minnesota, Patterson has grown through organic expansion and acquisitions into a roughly $6.5 billion revenue business serving two distinct end markets: dental professionals and veterinary/production animal customers.
The company operates as a value-added distributor — purchasing products from manufacturers, warehousing them, and delivering them to end-customers with bundled services including equipment installation, repair, financing, and software. This model generates thin operating margins (~3–5%) but relatively stable cash flows given the consumable, recurring nature of dental and animal health supply purchases.
Business Segments
Dental (~65% of Revenue, ~$4.0–4.1B)
The Dental segment serves approximately 90,000+ dental practice locations across the United States and Canada. Revenue breaks into three categories:
Consumables (~55% of Dental revenue): Dental supplies including impression materials, gloves, masks, infection control products, composite resins, cements, anesthetics, and other materials used daily in practice. This is the most predictable, recurring revenue stream.
Equipment (~30% of Dental revenue): Higher-ticket items including dental chairs, delivery units, x-ray systems (2D and CBCT 3D imaging), CAD/CAM systems (primarily Dentsply Sirona's CEREC system), digital intraoral scanners, sterilization equipment, and practice lighting. Equipment revenue is cyclical and lumpy.
Technology & Other (~15% of Dental revenue): Includes Fuse practice management software (cloud-based, launched ~2019 to replace legacy eazyDental/PracticeWorks), technical service contracts, e-commerce, and other services. Fuse is Patterson's attempt to compete with Henry Schein One (Dentrix/Eaglesoft) in the software-dependent dental practice workflow.
Key Dental Competitive Advantage (legacy): Historically, Patterson had an exclusive U.S. distribution agreement with Dentsply Sirona for CEREC CAD/CAM equipment, which gave it a meaningful edge in the high-margin equipment category. This exclusivity ended in 2018, and its loss accelerated dental market share erosion.
Animal Health (~35% of Revenue, ~$2.3–2.4B)
Patterson's Animal Health segment serves two channels:
Companion Animal (~60–65% of Animal Health revenue): Distributes pharmaceuticals, biologics (vaccines), parasiticides, and supplies to veterinary clinics. End market benefits from humanization of pets and growing veterinary spend per pet. Main products include Zoetis, Elanco, Merck Animal Health, and Boehringer Ingelheim products.
Production Animal (~35–40% of Animal Health revenue): Distributes products to livestock producers (cattle, swine, poultry). This segment is more commoditized and cyclical, tied to agricultural economics.
Patterson Animal Health competes primarily with MWI Animal Health (AmerisourceBergen subsidiary) and Covetrus (now private, formerly Henry Schein Animal Health spun out in 2019 and subsequently taken private by CD&R and TPG in 2022 for ~$4B).
Distribution Infrastructure
Patterson operates a North American distribution network:
- ~80 distribution centers across the U.S. and Canada (exact number varies with network optimization)
- Technology-enabled ordering: ecommerce platform and field sales force
- Field sales representatives: ~1,500+ dental sales reps; ~700+ animal health reps
- Technical service network: ~1,400 dental equipment technicians for installation and repair
This distribution network is capital-intensive to build but creates switching friction once embedded in a dental practice's workflow.
Go-to-Market Model
Patterson sells through:
- Field sales force — primary relationship with dental practices and vet clinics; compensated via commission
- eCommerce — growing channel for consumable reorders
- Inside sales / telesales — for smaller accounts
- Technology platform — Fuse and Patterson Technology products create "stickiness"
Revenue Mix by Geography
- ~85–87% United States
- ~13–15% Canada (primarily through Patterson Dental Canada and Bruker Canada Animal Health)
End-Market Dynamics
Dental: ~160,000 active dentists in the U.S.; practice is consolidating around DSOs (Dental Service Organizations like Aspen Dental, Pacific Dental, Heartland Dental), which negotiate volume pricing and favor Henry Schein and direct manufacturer purchasing. Independent practices (~60% of procedures) remain Patterson's core customer but are shrinking as a share of the market.
Animal Health: ~32,000 companion animal veterinary practices in the U.S.; growing through vet consolidation (VCA, National Veterinary Associates, PetVet). Production animal market is larger in absolute dollars but more commoditized.
Strategic Priorities (as of FY2024–FY2025)
Under CEO Don Zurbay (since Nov 2020):
- Grow Animal Health — viewed as higher-growth, less-disrupted segment
- Stabilize and differentiate Dental — through Fuse software adoption, DSO-focused go-to-market, and equipment/technology
- Cost efficiency — reduce SG&A as % of revenue; distribution network optimization
- Capital return — maintain dividend (~$1.04/share), measured buybacks
Key Concerns
- Sustained dental market share loss to HSIC
- Fuse adoption slower than anticipated; practice management software market dominated by Henry Schein One
- DSO growth structurally disadvantages Patterson's independent-practice-heavy customer base
- Animal Health growth insufficient to offset Dental headwinds at the consolidated level
Financial Snapshot
source: coverage-next-full ticker: PDCO step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
Step 04: Financial Snapshot
Income Statement Summary (FY2022–FY2024)
All figures in USD millions except per-share data.
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Revenue | $6,498 | $6,534 | $6,444 |
| Revenue Growth | +10.7% | +0.5% | -1.4% |
| Gross Profit | $1,207 | $1,208 | $1,194 |
| Gross Margin | 18.6% | 18.5% | 18.5% |
| SG&A | $893 | $925 | $921 |
| SG&A as % of Revenue | 13.7% | 14.2% | 14.3% |
| Operating Income (GAAP) | $314 | $283 | $273 |
| Operating Margin | 4.8% | 4.3% | 4.2% |
| Adjusted Operating Income* | ~$355 | ~$320 | ~$310 |
| Adjusted EBITDA* | ~$430 | ~$395 | ~$390 |
| Adjusted EBITDA Margin | ~6.6% | ~6.0% | ~6.1% |
| Interest Expense | ($48) | ($52) | ($54) |
| Pre-tax Income | $266 | $231 | $219 |
| Tax Rate (effective) | ~27% | ~27% | ~27% |
| Net Income (GAAP) | $194 | $169 | $160 |
| Net Margin | 3.0% | 2.6% | 2.5% |
| Adjusted Net Income* | ~$240 | ~$210 | ~$200 |
| Diluted Shares (millions) | 93.5 | 91.2 | 88.8 |
| GAAP EPS (diluted) | $2.07 | $1.85 | $1.80 |
| Adjusted EPS (diluted)* | ~$2.57 | ~$2.30 | ~$2.25 |
| DPS (dividends per share) | $1.04 | $1.04 | $1.04 |
*Adjusted figures exclude amortization of acquisition intangibles, restructuring charges, and other one-time items. Company reports non-GAAP adjusted EPS as primary earnings metric.
Gross Margin Analysis
Patterson's gross margin has been remarkably stable at ~18.4–18.6% over recent years. This stability reflects:
- Mix shift offsetting pricing pressure: Higher-margin consumables and technology/services partially offsetting lower-margin equipment growth
- Animal Health dilution: Animal Health gross margins (~14–15%) are significantly below Dental (~22–23%), and Animal Health is growing faster — creating structural gross margin pressure
- Pricing power: Inflation pass-through in consumables has supported gross margin stability despite input cost pressure
Segment Gross Margins (estimated):
| Segment | Gross Margin | Notes |
|---|---|---|
| Dental | ~22–23% | Software/services higher; equipment lower |
| Animal Health | ~14–15% | Commoditized pharma distribution; low-margin production animal drag |
| Consolidated | ~18.5% | Blended |
Operating Expense Trend
SG&A has been rising as a % of revenue (13.7% → 14.3%) despite cost efficiency initiatives. Drivers:
- Sales force investments in DSO capabilities
- Technology infrastructure (Fuse development, ecommerce)
- Headcount to support Animal Health growth
- Inflationary wage pressure on ~7,000+ employee base
Management targets SG&A leverage over time but has not yet demonstrated it in recent periods.
EBITDA Detail
| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Operating Income (GAAP) | $314 | $283 | $273 |
| + D&A | ~$85 | ~$88 | ~$90 |
| EBITDA | ~$399 | ~$371 | ~$363 |
| + Stock comp | ~$25 | ~$25 | ~$25 |
| + Restructuring/other | ~$8 | ~$8 | ~$10 |
| Adjusted EBITDA | ~$432 | ~$404 | ~$398 |
Earnings Per Share Bridge
EPS has declined from $2.07 (FY2022) to $1.80 (FY2024) on a GAAP basis, despite share buybacks reducing the diluted share count from 93.5M to 88.8M. The ~5% reduction in share count provided roughly $0.10 of EPS support, meaning underlying earnings declined more than headline EPS suggests.
Adjusted EPS (~$2.25 in FY2024) provides a cleaner picture of operating performance, though management's add-backs (primarily amortization of ~$40M annually from prior acquisitions) are legitimate and should continue declining as older acquisition intangibles amortize off.
Profitability vs. Peers
| Company | Revenue | Gross Margin | EBITDA Margin | P/E |
|---|---|---|---|---|
| Patterson (PDCO) | $6.4B | 18.5% | ~6.1% | ~12x adj. |
| Henry Schein (HSIC) | ~$13B | ~21% | ~8–9% | ~15–16x adj. |
| McKesson (MCK) | ~$300B | ~4–5% | ~1.5% | ~20x |
Patterson trades at a meaningful discount to HSIC on EBITDA margin (reflecting less software/services content and more commoditized Animal Health mix) and on P/E multiple (reflecting share loss narrative).
Key Financial Concerns
- Revenue contraction in FY2024: First year of negative revenue growth in 5+ years; reflects dental structural issues
- Margin pressure: Operating margin declining from 4.8% (FY2022) to 4.2% (FY2024) as revenue base shrinks
- EPS trajectory: GAAP EPS declining despite buybacks; consensus expects modest improvement in FY2025 but uncertainty is high
- Dividend sustainability: $1.04/share dividend costs
$92M/year; free cash flow ($250–300M) comfortably covers this but if earnings deteriorate further, dividend coverage becomes a concern
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $PDCO.